Eckert & Ziegler stock: November 12 report tests Eckert & Ziegler stock

Published on 10/20/2026 at 16:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit EUR 149.30 million in first-half 2026. Eckert & Ziegler stock costs EUR 12.85 on October 20, 2026, down 0.54 percent versus Xetra close.

Reporting date and earnings

The next quarterly report is scheduled for November 12, 2026.
First-half revenue reached EUR 149.30 million, up 0.34 percent year over year.
Eckert & Ziegler stock costs EUR 12.85 at Lang & Schwarz on October 20, 2026 at 4:11 p.m. CEST, 0.54 percent below the Xetra close of October 19, 2026.
Market capitalization stood at EUR 802.9 million on October 20, 2026.

Isometrische 3D-Illustration der radiopharmazeutischen Lieferkette von Produktion bis Krankenhaus — Eckert & Ziegler DE0005659700 Medizintechnik: Isometrisches 3D-Diagramm der radiopharmazeutischen Wertschöpfungskette bis Klinik, Illustration mit AI erstellt.

Eckert & Ziegler stock (ISIN DE0005659700) has its next quarterly reporting date on November 12, 2026, according to Kapitalmarktexperten. The report will provide the next published test of the earnings expectations currently attached to the company. Eckert & Ziegler stock was trading at EUR 12.85 at Lang & Schwarz on October 20, 2026 at 4:11 p.m. CEST, down 0.54 percent versus the Xetra close of October 19, 2026 at EUR 12.92.

What will November 12 test?

The third-quarter report will be measured against the first-half figures released on August 13, 2026. According to 4investors, revenue reached EUR 149.30 million, up 0.34 percent from EUR 148.80 million in the first half of 2025. Net income rose 4.67 percent to EUR 22.40 million, while adjusted EBIT fell 5.93 percent to EUR 33.30 million.

The company confirmed full-year 2026 guidance for revenue of around EUR 320.00 million and adjusted EBIT of around EUR 80.00 million in the same August release. The upcoming report therefore matters most for the conversion of sales into operating profit, rather than for revenue alone.

Stock position and valuation

The EUR 12.85 Lang & Schwarz price stood EUR 4.88, or 27.52 percent, below the 52-week high of EUR 17.73 and EUR 0.94, or 7.89 percent, above the 52-week low of EUR 11.91 on October 20, 2026. The market capitalization was EUR 802.9 million, and the price-to-earnings ratio was 16.23 on the same date.

Borse Online reported on October 19, 2026 that NuWays kept a Buy rating and a 12-month target of EUR 21.50. That target is 67.32 percent above the Lang & Schwarz price, while the next quarterly report offers the nearer operating checkpoint.

Comparison with peers

Eckert & Ziegler: down 0.54 percent, P/E 16.23, market capitalization EUR 802.9 million on October 20, 2026.
Siemens Healthineers (Xetra, EUR): up 1.15 percent, P/E 20.93, market capitalization EUR 46.4 billion on October 20, 2026.
Sartorius (Xetra, EUR): up 0.35 percent, P/E 92.76, market capitalization EUR 16.1 billion on October 20, 2026.

Next checkpoint for investors

The November 12 report can clarify whether adjusted EBIT growth is returning after the first-half decline. Until then, the stock remains positioned between its 52-week low and high, with the latest valuation below the peer multiples shown above.

The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.